17097378

Source:http://linkedlifedata.com/resource/pubmed/id/17097378

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0024501, umls-concept:C0034656, umls-concept:C0040808, umls-concept:C0087111, umls-concept:C0205267, umls-concept:C0406317, umls-concept:C0439234, umls-concept:C0549178, umls-concept:C0666743, umls-concept:C1707455
pubmed:issue	1
pubmed:dateCreated	2006-12-27
pubmed:abstractText	Previous studies of infliximab in psoriasis have demonstrated rapid improvement with induction therapy and sustained response with regularly administered maintenance therapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7907132
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/infliximab
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1097-6787
pubmed:author	pubmed-author:ArnoldCynthiaC, pubmed-author:DooleyLisa TLT, pubmed-author:EvansRobertR, pubmed-author:FeldmanSteven RSR, pubmed-author:GottliebAlice BAB, pubmed-author:GuzzoCynthiaC, pubmed-author:LiShuS, pubmed-author:MenterAlanA, pubmed-author:PappKimK, pubmed-author:WeinsteinGerald DGD
pubmed:issnType	Electronic
pubmed:volume	56
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	31.e1-15
pubmed:meshHeading	pubmed-meshheading:17097378-Adult, pubmed-meshheading:17097378-Antibodies, Monoclonal, pubmed-meshheading:17097378-Arthritis, Psoriatic, pubmed-meshheading:17097378-Canada, pubmed-meshheading:17097378-Cross-Over Studies, pubmed-meshheading:17097378-Double-Blind Method, pubmed-meshheading:17097378-Drug Administration Schedule, pubmed-meshheading:17097378-Europe, pubmed-meshheading:17097378-Female, pubmed-meshheading:17097378-Humans, pubmed-meshheading:17097378-Immunosuppressive Agents, pubmed-meshheading:17097378-Infusions, Intravenous, pubmed-meshheading:17097378-Lupus Erythematosus, Systemic, pubmed-meshheading:17097378-Male, pubmed-meshheading:17097378-Middle Aged, pubmed-meshheading:17097378-Neoplasms, pubmed-meshheading:17097378-Patients, pubmed-meshheading:17097378-Psoriasis, pubmed-meshheading:17097378-Quality of Life, pubmed-meshheading:17097378-Questionnaires, pubmed-meshheading:17097378-Severity of Illness Index, pubmed-meshheading:17097378-Treatment Outcome, pubmed-meshheading:17097378-Tuberculosis, pubmed-meshheading:17097378-United States
pubmed:year	2007
pubmed:articleTitle	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
pubmed:affiliation	Division of Dermatology, Baylor University Medical Center, UT Southwestern Medical School, 5310 Harvest Hill Rd, Ste 260, Dallas, TX 75230, USA. amderm@gmail.com
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study